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Royal Devon and Exeter Hospitals, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, United KingdomMost vascular surgeons know a little about coagulation and
have a lot of experience of haemorrhage. Faced with the
patient bleeding to death during repair of a ruptured AAA,
desperation can set in. The imperative to do something is
a primal drive; the psychological concept of “anticipated
regret” of the patient’s death. Another factor is the “rule of
rescue” where logic and rational decision-making are
overwhelmed by the desire to act. We have all been there.
Failure of all conventional means to stop bleeding leads
to a desparate search for alternatives. One is the ‘off label’
administration of rFVIIa, which promotes a one-off burst of
thrombin. Tissue factor, activated platelets and factor X are
required as co-factors. Hypoﬁbrinogenaemia and thrombo-
cytopaenia will prevent rFVIIa from forming a good hae-
mostatic plug and unfortunately both are a feature of the
dilutional coagulopathy associated with massive blood loss.
Hypothermia and acidosis also reduce the efﬁcacy of rFVIIa.
For this reason, guidelines suggest that these factors should
be reversed by the administration of ﬁbrinogen and anti-
ﬁbrinolytics, aggressive warming, volume resuscitation and
correction of acid base status before rFVIIa is given.
In this study, the authors have made great efforts to
analyse the results of rFVIIa administration in a mixed group
of AAA patients including elective, ruptured and EVAR. The
results indicate that a large number of “non-responders”
(within a subjective and categorical judgement of ‘stopped
bleeding, attenuated or unchanged’) were acidotic and
probably unsalvageable. Moreover 82% received an inade-
quate single-vial dose. The recommended dose of rFVIIa for
an 80 kg male costs V2350. There is, therefore, a ﬁnancial
incentive for the promotion of the use of this drug.
There have always been concerns about the thrombo-
embolic (TE) side effects of procoagulant drugs such as
fVIIa and that they may be dose related. In this study 44%
of the patients who experienced TE complications receivedDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.01.028
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http://dx.doi.org/10.1016/j.ejvs.2013.03.001more than one vial, which adds weight to this argument,
although numbers are too small to draw deﬁnite
conclusions.
Between 2000 and 2008, off label use of rVIIa increased
140 fold in the USA; whereas its licensed use in the treat-
ment of haemophilia increased less than fourfold. A recent
Cochrane review of 29 randomised trials, 28 of which were
placebo controlled, concluded “The effectiveness of rFVIIa
as a more general haemostatic drug, either prophylactically
or therapeutically, remains unproven. The results indicate
increased risk of arterial events in patients receiving rFVIIa.
The use of rFVIIa outside its current licensed indications
should be restricted to clinical trials”.1
The exemplary CRASH-II trial of tranexamic acid vs
placebo randomised 20,211 patients in 40 countries and
proved beyond doubt that the intervention reduced the risk
of death in bleeding patients when given within three
hours.2 Tranexamic acid is a cheap, generic, safe drug. We
may throw the baby out with the bathwater if we conclude
that rFVIIa is an expensive, unsafe drug and I would concur
with the authors in their conclusion that more trial data is
urgently required.REFERENCES
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